ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Long-Term Outcomes of Liver Transplantation in Patients with Pre-Transplant Renal Dysfunction Treated with Induction Therapy and Delayed Reduced De Novo Once-Daily Tacrolimus

M. Gastaca,1 J. Bustamante,2 A. Ventoso,1 J. Fernandez,2 P. Ruiz,1 M. Testillano,2 M. Prieto,1 P. Salvador,2 I. Palomares,1 M. Senosiain,2 M. Suarez,2 A. Valdivieso.1

1Hepatobiliary Surgery and Liver Transplant Unit, Cruces University Hospital, Bilbao, Spain
2Hepatology Unit, Cruces University Hospital, Bilbao, Spain.

Meeting: 2018 American Transplant Congress

Abstract number: C204

Keywords: FK506, Immunosuppression, Renal function, Survival

Session Information

Session Name: Poster Session C: Liver: Immunosuppression and Rejection

Session Type: Poster Session

Date: Monday, June 4, 2018

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:00pm-7:00pm

Location: Hall 4EF

AIM: To describe the long-term outcome of liver transplantation (LT) in patients with pre-transplant renal dysfunction treated with induction therapy and delayed reduced de novo once-daily tacrolimus (T-QD).

PATIENTS AND METHODS: Adult patients with pre-transplant renal dysfunction who received a LT between April 2008 and August 2011 whose initial immunosuppression was based on induction therapy and delayed de novo T-QD comprised the study cohort. Renal function was assessed through the MDRD-4 formula; renal dysfunction was defined as eGFR <60 ml/min. IL-2 receptor antagonists were used for induction therapy and T-QD was started de novo either by oral route or through a naso-gastric tube as soon as the renal function was stabilized. Initial dose of T-QD was 0.1 mg/kg/day or 0.07 mg/kg/day when combined with MMF. Steroids were always used and MMF was indicated according to clinical criteria.

RESULTS: The final sample consisted of 19 patients with a median follow-up of 57.1 months (range 10.3-77.7). Mean pre-transplant eGFR was 45.9± 10.8 ml/min. T-QD was initiated within the first week in 13 patients (68.4%). All patients were on T-QD based therapy by the end of the second week. MMF was initiated in sixteen patients (84.2%) within the first 15 days after transplantation. Evolution of mean Tac trough levels and eGFR at D15, D30, 1 year, 3 years and 5 years were as follows: 5.4 ± 2.2, 4.8 ± 2.1, 5.8 ± 2.5, 3.1 ± 2.0 and 4.2 ± 2.4 ng/mL for the Tac levels and 74.4 ± 25.1, 65.6 ± 23.2, 55.3 ± 11.7, 54.9 ± 11.9 and 55.3 ± 12.7 ml/min for eGFR. T-QD withdrawal occurred in 6 patients (31.6); patients were switched to MMF mono therapy. No patient needed dialysis or kidney transplantation. Biopsy proven acute rejection was observed in 3 patients (15.8%); one of them needed steroid boluses. Five patients (26.3%) developed new onset DM. 1- and 5-year patient survival was 94.7% and 78.9%, respectively.

CONCLUSION: Induction therapy with delayed introduction of de novo once-daily tacrolimus followed by the maintenance of reduced levels of tacrolimus preserves long-term renal function and achieves favorable patient survival in patients with pre-transplant renal dysfunction.

CITATION INFORMATION: Gastaca M., Bustamante J., Ventoso A., Fernandez J., Ruiz P., Testillano M., Prieto M., Salvador P., Palomares I., Senosiain M., Suarez M., Valdivieso A. Long-Term Outcomes of Liver Transplantation in Patients with Pre-Transplant Renal Dysfunction Treated with Induction Therapy and Delayed Reduced De Novo Once-Daily Tacrolimus Am J Transplant. 2017;17 (suppl 3).

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Gastaca M, Bustamante J, Ventoso A, Fernandez J, Ruiz P, Testillano M, Prieto M, Salvador P, Palomares I, Senosiain M, Suarez M, Valdivieso A. Long-Term Outcomes of Liver Transplantation in Patients with Pre-Transplant Renal Dysfunction Treated with Induction Therapy and Delayed Reduced De Novo Once-Daily Tacrolimus [abstract]. https://atcmeetingabstracts.com/abstract/long-term-outcomes-of-liver-transplantation-in-patients-with-pre-transplant-renal-dysfunction-treated-with-induction-therapy-and-delayed-reduced-de-novo-once-daily-tacrolimus/. Accessed June 2, 2025.

« Back to 2018 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences